Pediapred

Stevens-Johnson Syndrome, Ophthalmia, Sympathetic, Chorioretinitis + 103 more

Treatment

4 FDA approvals

20 Active Studies for Pediapred

What is Pediapred

Prednisolone

The Generic name of this drug

Treatment Summary

Prednisolone phosphate is a steroid drug used to reduce inflammation, suppress the immune system, and prevent tumor growth. It was approved by the FDA in 1973 and is similar to cortisol.

Prednisolone

is the brand name

image of different drug pills on a surface

Pediapred Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Prednisolone

Prednisolone

1974

37

Approved as Treatment by the FDA

Prednisolone, otherwise known as Prednisolone, is approved by the FDA for 4 uses including Pneumocystis Jirovecii Pneumonia and Ulcerative Colitis .

Pneumocystis Jirovecii Pneumonia

Used in combination with Dapsone to help manage Pneumocystis Jirovecii Pneumonia

Ulcerative Colitis

Helps manage Ulcerative Colitis

Pneumonia, Pneumocystis

Used in combination with Dapsone to help manage Pneumocystis Jirovecii Pneumonia

Ulcerative Colitis

Helps manage Ulcerative Colitis

Effectiveness

How Pediapred Affects Patients

Prednisolone is a corticosteroid drug that works by blocking pro-inflammatory signals and encouraging anti-inflammatory signals. Its effects do not last very long, as it has a half-life of 2-4 hours. It has a wide range of effective dosages, and much more than what the body would normally produce. Taking this drug carries risks, including weakening the body's natural ability to fight infections and suppressing hormones produced by the hypothalamus, pituitary gland, and adrenal glands.

How Pediapred works in the body

Corticosteroids help reduce inflammation. They work by binding to a receptor in the body that changes the activity of certain genes. Corticosteroids stop white blood cells from accumulating at sites of inflammation, and also stop molecules that cause inflammation from forming. Lower doses of corticosteroids act as an anti-inflammatory, while higher doses reduce the body's immune response. When high doses of corticosteroids are taken for a long period of time, they can cause an imbalance of sodium and potassium levels in the body.

When to interrupt dosage

The recommended dosage of Pediapred is contingent upon the certified situation, including Uveitis, Ocular Inflammation and Ophthalmia, Sympathetic. The amount of dosage fluctuates in accordance with the method of delivery indicated in the table below.

Condition

Dosage

Administration

Communicable Diseases

, 15.0 mg/mL, 25.0 mg/mL, 10.0 mg, 30.0 mg, 15.0 mg, 10.0 mg/mL, 5.0 mg/mL, 5.0 mg/mg, 20.0 mg/mL, 1.2 mg/mL, 5.0 mg, 1.0 mg, 25.0 mg, 20.0 mg, 0.004 mg/mg, 16.7 mg/mL

Ointment - Ophthalmic, , Ophthalmic, Oral, Solution, Solution - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Syrup, Syrup - Oral, Solution / drops - Ophthalmic, Tablet, Tablet - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension / drops - Ophthalmic, Suspension - Ophthalmic, Liquid, Liquid - Oral, Ophthalmic; Topical, Topical, Ointment, Ointment - Topical

Bacterial Infections

, 15.0 mg/mL, 25.0 mg/mL, 10.0 mg, 30.0 mg, 15.0 mg, 10.0 mg/mL, 5.0 mg/mL, 5.0 mg/mg, 20.0 mg/mL, 1.2 mg/mL, 5.0 mg, 1.0 mg, 25.0 mg, 20.0 mg, 0.004 mg/mg, 16.7 mg/mL

Ointment - Ophthalmic, , Ophthalmic, Oral, Solution, Solution - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Syrup, Syrup - Oral, Solution / drops - Ophthalmic, Tablet, Tablet - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension / drops - Ophthalmic, Suspension - Ophthalmic, Liquid, Liquid - Oral, Ophthalmic; Topical, Topical, Ointment, Ointment - Topical

Brain

, 15.0 mg/mL, 25.0 mg/mL, 10.0 mg, 30.0 mg, 15.0 mg, 10.0 mg/mL, 5.0 mg/mL, 5.0 mg/mg, 20.0 mg/mL, 1.2 mg/mL, 5.0 mg, 1.0 mg, 25.0 mg, 20.0 mg, 0.004 mg/mg, 16.7 mg/mL

Ointment - Ophthalmic, , Ophthalmic, Oral, Solution, Solution - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Syrup, Syrup - Oral, Solution / drops - Ophthalmic, Tablet, Tablet - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension / drops - Ophthalmic, Suspension - Ophthalmic, Liquid, Liquid - Oral, Ophthalmic; Topical, Topical, Ointment, Ointment - Topical

Rheumatoid Arthritis

, 15.0 mg/mL, 25.0 mg/mL, 10.0 mg, 30.0 mg, 15.0 mg, 10.0 mg/mL, 5.0 mg/mL, 5.0 mg/mg, 20.0 mg/mL, 1.2 mg/mL, 5.0 mg, 1.0 mg, 25.0 mg, 20.0 mg, 0.004 mg/mg, 16.7 mg/mL

Ointment - Ophthalmic, , Ophthalmic, Oral, Solution, Solution - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Syrup, Syrup - Oral, Solution / drops - Ophthalmic, Tablet, Tablet - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension / drops - Ophthalmic, Suspension - Ophthalmic, Liquid, Liquid - Oral, Ophthalmic; Topical, Topical, Ointment, Ointment - Topical

Tuberculosis

, 15.0 mg/mL, 25.0 mg/mL, 10.0 mg, 30.0 mg, 15.0 mg, 10.0 mg/mL, 5.0 mg/mL, 5.0 mg/mg, 20.0 mg/mL, 1.2 mg/mL, 5.0 mg, 1.0 mg, 25.0 mg, 20.0 mg, 0.004 mg/mg, 16.7 mg/mL

Ointment - Ophthalmic, , Ophthalmic, Oral, Solution, Solution - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Syrup, Syrup - Oral, Solution / drops - Ophthalmic, Tablet, Tablet - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension / drops - Ophthalmic, Suspension - Ophthalmic, Liquid, Liquid - Oral, Ophthalmic; Topical, Topical, Ointment, Ointment - Topical

Arthritis, Juvenile

, 15.0 mg/mL, 25.0 mg/mL, 10.0 mg, 30.0 mg, 15.0 mg, 10.0 mg/mL, 5.0 mg/mL, 5.0 mg/mg, 20.0 mg/mL, 1.2 mg/mL, 5.0 mg, 1.0 mg, 25.0 mg, 20.0 mg, 0.004 mg/mg, 16.7 mg/mL

Ointment - Ophthalmic, , Ophthalmic, Oral, Solution, Solution - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Syrup, Syrup - Oral, Solution / drops - Ophthalmic, Tablet, Tablet - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension / drops - Ophthalmic, Suspension - Ophthalmic, Liquid, Liquid - Oral, Ophthalmic; Topical, Topical, Ointment, Ointment - Topical

Aspergillosis, Allergic Bronchopulmonary

, 15.0 mg/mL, 25.0 mg/mL, 10.0 mg, 30.0 mg, 15.0 mg, 10.0 mg/mL, 5.0 mg/mL, 5.0 mg/mg, 20.0 mg/mL, 1.2 mg/mL, 5.0 mg, 1.0 mg, 25.0 mg, 20.0 mg, 0.004 mg/mg, 16.7 mg/mL

Ointment - Ophthalmic, , Ophthalmic, Oral, Solution, Solution - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Syrup, Syrup - Oral, Solution / drops - Ophthalmic, Tablet, Tablet - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension / drops - Ophthalmic, Suspension - Ophthalmic, Liquid, Liquid - Oral, Ophthalmic; Topical, Topical, Ointment, Ointment - Topical

Trichinosis

, 15.0 mg/mL, 25.0 mg/mL, 10.0 mg, 30.0 mg, 15.0 mg, 10.0 mg/mL, 5.0 mg/mL, 5.0 mg/mg, 20.0 mg/mL, 1.2 mg/mL, 5.0 mg, 1.0 mg, 25.0 mg, 20.0 mg, 0.004 mg/mg, 16.7 mg/mL

Ointment - Ophthalmic, , Ophthalmic, Oral, Solution, Solution - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Syrup, Syrup - Oral, Solution / drops - Ophthalmic, Tablet, Tablet - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension / drops - Ophthalmic, Suspension - Ophthalmic, Liquid, Liquid - Oral, Ophthalmic; Topical, Topical, Ointment, Ointment - Topical

Red-Cell Aplasia, Pure

, 15.0 mg/mL, 25.0 mg/mL, 10.0 mg, 30.0 mg, 15.0 mg, 10.0 mg/mL, 5.0 mg/mL, 5.0 mg/mg, 20.0 mg/mL, 1.2 mg/mL, 5.0 mg, 1.0 mg, 25.0 mg, 20.0 mg, 0.004 mg/mg, 16.7 mg/mL

Ointment - Ophthalmic, , Ophthalmic, Oral, Solution, Solution - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Syrup, Syrup - Oral, Solution / drops - Ophthalmic, Tablet, Tablet - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension / drops - Ophthalmic, Suspension - Ophthalmic, Liquid, Liquid - Oral, Ophthalmic; Topical, Topical, Ointment, Ointment - Topical

Ulcerative Colitis

, 15.0 mg/mL, 25.0 mg/mL, 10.0 mg, 30.0 mg, 15.0 mg, 10.0 mg/mL, 5.0 mg/mL, 5.0 mg/mg, 20.0 mg/mL, 1.2 mg/mL, 5.0 mg, 1.0 mg, 25.0 mg, 20.0 mg, 0.004 mg/mg, 16.7 mg/mL

Ointment - Ophthalmic, , Ophthalmic, Oral, Solution, Solution - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Syrup, Syrup - Oral, Solution / drops - Ophthalmic, Tablet, Tablet - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension / drops - Ophthalmic, Suspension - Ophthalmic, Liquid, Liquid - Oral, Ophthalmic; Topical, Topical, Ointment, Ointment - Topical

Lupus

, 15.0 mg/mL, 25.0 mg/mL, 10.0 mg, 30.0 mg, 15.0 mg, 10.0 mg/mL, 5.0 mg/mL, 5.0 mg/mg, 20.0 mg/mL, 1.2 mg/mL, 5.0 mg, 1.0 mg, 25.0 mg, 20.0 mg, 0.004 mg/mg, 16.7 mg/mL

Ointment - Ophthalmic, , Ophthalmic, Oral, Solution, Solution - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Syrup, Syrup - Oral, Solution / drops - Ophthalmic, Tablet, Tablet - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension / drops - Ophthalmic, Suspension - Ophthalmic, Liquid, Liquid - Oral, Ophthalmic; Topical, Topical, Ointment, Ointment - Topical

Relapsing Polychondritis

, 15.0 mg/mL, 25.0 mg/mL, 10.0 mg, 30.0 mg, 15.0 mg, 10.0 mg/mL, 5.0 mg/mL, 5.0 mg/mg, 20.0 mg/mL, 1.2 mg/mL, 5.0 mg, 1.0 mg, 25.0 mg, 20.0 mg, 0.004 mg/mg, 16.7 mg/mL

Ointment - Ophthalmic, , Ophthalmic, Oral, Solution, Solution - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Syrup, Syrup - Oral, Solution / drops - Ophthalmic, Tablet, Tablet - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension / drops - Ophthalmic, Suspension - Ophthalmic, Liquid, Liquid - Oral, Ophthalmic; Topical, Topical, Ointment, Ointment - Topical

Anemia, Diamond-Blackfan

, 15.0 mg/mL, 25.0 mg/mL, 10.0 mg, 30.0 mg, 15.0 mg, 10.0 mg/mL, 5.0 mg/mL, 5.0 mg/mg, 20.0 mg/mL, 1.2 mg/mL, 5.0 mg, 1.0 mg, 25.0 mg, 20.0 mg, 0.004 mg/mg, 16.7 mg/mL

Ointment - Ophthalmic, , Ophthalmic, Oral, Solution, Solution - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Syrup, Syrup - Oral, Solution / drops - Ophthalmic, Tablet, Tablet - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension / drops - Ophthalmic, Suspension - Ophthalmic, Liquid, Liquid - Oral, Ophthalmic; Topical, Topical, Ointment, Ointment - Topical

Thyroiditis

, 15.0 mg/mL, 25.0 mg/mL, 10.0 mg, 30.0 mg, 15.0 mg, 10.0 mg/mL, 5.0 mg/mL, 5.0 mg/mg, 20.0 mg/mL, 1.2 mg/mL, 5.0 mg, 1.0 mg, 25.0 mg, 20.0 mg, 0.004 mg/mg, 16.7 mg/mL

Ointment - Ophthalmic, , Ophthalmic, Oral, Solution, Solution - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Syrup, Syrup - Oral, Solution / drops - Ophthalmic, Tablet, Tablet - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension / drops - Ophthalmic, Suspension - Ophthalmic, Liquid, Liquid - Oral, Ophthalmic; Topical, Topical, Ointment, Ointment - Topical

Thrombocytopenia

, 15.0 mg/mL, 25.0 mg/mL, 10.0 mg, 30.0 mg, 15.0 mg, 10.0 mg/mL, 5.0 mg/mL, 5.0 mg/mg, 20.0 mg/mL, 1.2 mg/mL, 5.0 mg, 1.0 mg, 25.0 mg, 20.0 mg, 0.004 mg/mg, 16.7 mg/mL

Ointment - Ophthalmic, , Ophthalmic, Oral, Solution, Solution - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Syrup, Syrup - Oral, Solution / drops - Ophthalmic, Tablet, Tablet - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension / drops - Ophthalmic, Suspension - Ophthalmic, Liquid, Liquid - Oral, Ophthalmic; Topical, Topical, Ointment, Ointment - Topical

Corneal Injuries

, 15.0 mg/mL, 25.0 mg/mL, 10.0 mg, 30.0 mg, 15.0 mg, 10.0 mg/mL, 5.0 mg/mL, 5.0 mg/mg, 20.0 mg/mL, 1.2 mg/mL, 5.0 mg, 1.0 mg, 25.0 mg, 20.0 mg, 0.004 mg/mg, 16.7 mg/mL

Ointment - Ophthalmic, , Ophthalmic, Oral, Solution, Solution - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Syrup, Syrup - Oral, Solution / drops - Ophthalmic, Tablet, Tablet - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension / drops - Ophthalmic, Suspension - Ophthalmic, Liquid, Liquid - Oral, Ophthalmic; Topical, Topical, Ointment, Ointment - Topical

Dermatomyositis

, 15.0 mg/mL, 25.0 mg/mL, 10.0 mg, 30.0 mg, 15.0 mg, 10.0 mg/mL, 5.0 mg/mL, 5.0 mg/mg, 20.0 mg/mL, 1.2 mg/mL, 5.0 mg, 1.0 mg, 25.0 mg, 20.0 mg, 0.004 mg/mg, 16.7 mg/mL

Ointment - Ophthalmic, , Ophthalmic, Oral, Solution, Solution - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Syrup, Syrup - Oral, Solution / drops - Ophthalmic, Tablet, Tablet - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension / drops - Ophthalmic, Suspension - Ophthalmic, Liquid, Liquid - Oral, Ophthalmic; Topical, Topical, Ointment, Ointment - Topical

Optic Neuritis

, 15.0 mg/mL, 25.0 mg/mL, 10.0 mg, 30.0 mg, 15.0 mg, 10.0 mg/mL, 5.0 mg/mL, 5.0 mg/mg, 20.0 mg/mL, 1.2 mg/mL, 5.0 mg, 1.0 mg, 25.0 mg, 20.0 mg, 0.004 mg/mg, 16.7 mg/mL

Ointment - Ophthalmic, , Ophthalmic, Oral, Solution, Solution - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Syrup, Syrup - Oral, Solution / drops - Ophthalmic, Tablet, Tablet - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension / drops - Ophthalmic, Suspension - Ophthalmic, Liquid, Liquid - Oral, Ophthalmic; Topical, Topical, Ointment, Ointment - Topical

Proctitis

, 15.0 mg/mL, 25.0 mg/mL, 10.0 mg, 30.0 mg, 15.0 mg, 10.0 mg/mL, 5.0 mg/mL, 5.0 mg/mg, 20.0 mg/mL, 1.2 mg/mL, 5.0 mg, 1.0 mg, 25.0 mg, 20.0 mg, 0.004 mg/mg, 16.7 mg/mL

Ointment - Ophthalmic, , Ophthalmic, Oral, Solution, Solution - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Syrup, Syrup - Oral, Solution / drops - Ophthalmic, Tablet, Tablet - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension / drops - Ophthalmic, Suspension - Ophthalmic, Liquid, Liquid - Oral, Ophthalmic; Topical, Topical, Ointment, Ointment - Topical

Anemia, Hemolytic

, 15.0 mg/mL, 25.0 mg/mL, 10.0 mg, 30.0 mg, 15.0 mg, 10.0 mg/mL, 5.0 mg/mL, 5.0 mg/mg, 20.0 mg/mL, 1.2 mg/mL, 5.0 mg, 1.0 mg, 25.0 mg, 20.0 mg, 0.004 mg/mg, 16.7 mg/mL

Ointment - Ophthalmic, , Ophthalmic, Oral, Solution, Solution - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Syrup, Syrup - Oral, Solution / drops - Ophthalmic, Tablet, Tablet - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension / drops - Ophthalmic, Suspension - Ophthalmic, Liquid, Liquid - Oral, Ophthalmic; Topical, Topical, Ointment, Ointment - Topical

Warnings

Pediapred Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Prednisolone may interact with Pulse Frequency

There are 20 known major drug interactions with Pediapred.

Common Pediapred Drug Interactions

Drug Name

Risk Level

Description

2-Methoxyethanol

Major

The risk or severity of adverse effects can be increased when Prednisolone is combined with 2-Methoxyethanol.

9-(N-methyl-L-isoleucine)-cyclosporin A

Major

The risk or severity of adverse effects can be increased when Prednisolone is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.

Abatacept

Major

The risk or severity of adverse effects can be increased when Prednisolone is combined with Abatacept.

Abemaciclib

Major

The metabolism of Abemaciclib can be increased when combined with Prednisolone.

Abetimus

Major

The risk or severity of adverse effects can be increased when Prednisolone is combined with Abetimus.

Pediapred Toxicity & Overdose Risk

Not much is known about overdosing on prednisone, but those who take too much for a long period of time may show signs such as confusion, a round face, extra fat deposits, and water retention. If someone has taken too much prednisone orally, they should be given their stomach pumped or made to vomit. If someone has been taking too much prednisone for a long time, their dosage should be lowered or taken every other day.

image of a doctor in a lab doing drug, clinical research

Pediapred Novel Uses: Which Conditions Have a Clinical Trial Featuring Pediapred?

115 active clinical trials are currently in progress to examine the potential of Pediapred in alleviating Ocular Inflammation, Uveitis, Sympathetic Ophthalmia and other conditions.

Condition

Clinical Trials

Trial Phases

Red-Cell Aplasia, Pure

0 Actively Recruiting

Dermatitis, Allergic Contact

0 Actively Recruiting

Asthma

0 Actively Recruiting

Ulcerative Colitis

14 Actively Recruiting

Phase 3, Phase 2, Not Applicable, Phase 4, Phase 1

Hot Water Burns (Scalds)

0 Actively Recruiting

Anemia, Diamond-Blackfan

4 Actively Recruiting

Not Applicable, Phase 1, Phase 2

Lupus

65 Actively Recruiting

Phase 2, Not Applicable, Phase 1, Phase 3, Phase 4, Early Phase 1

Mycosis Fungoides

0 Actively Recruiting

Degenerative polyarthritis

13 Actively Recruiting

Not Applicable, Early Phase 1, Phase 3, Phase 2

Nephrotic Syndrome

5 Actively Recruiting

Phase 2, Not Applicable, Phase 3

Sarcoidosis

10 Actively Recruiting

Phase 4, Phase 2, Not Applicable, Phase 3

Thrombocytopenia

0 Actively Recruiting

Brain

0 Actively Recruiting

Dermatomyositis

0 Actively Recruiting

Eosinophilic Pneumonia

0 Actively Recruiting

Organ Transplantation

0 Actively Recruiting

Congenital adrenal hyperplasia

7 Actively Recruiting

Phase 3, Phase 1, Phase 2, Not Applicable

Eczema

0 Actively Recruiting

Eczema

0 Actively Recruiting

Pemphigus

0 Actively Recruiting

Pediapred Reviews: What are patients saying about Pediapred?

4

Patient Review

2/12/2008

Pediapred for Asthma

My 3 year old takes this for asthma/wheezing/breathing problems. The only problem I've had with it is that is makes him very cranky & grouchy, more so than a 3 year old would usually be.

4

Patient Review

12/14/2008

Pediapred for Asthma

This medicine is great! My 6 year old daughter uses this to treat her asthma attacks and I have never found anything else that works this well. The only complaint that I have is it tastes horrible. Other than it making her hungry and a little on the touchy side (cries at the littlest things) this medicine is wonderful.

3.3

Patient Review

12/18/2009

Pediapred for Asthma

While this medicine did reduce my 1 year old's slight wheezing, it also gave him a terrible case of thrush and a yeast infection that was even more painful, and long lasting.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about pediapred

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Pediapred liquid?

"PEDIAPRED® Oral Solution is a colorless to light straw-colored, raspberry flavored solution. Each 5 mL (teaspoonful) of PEDIAPRED® Oral Solution contains 6.7 mg PEDIAPRED® (5 mg prednisolone base) in a palatable, aqueous vehicle."

Answered by AI

What is prednisolone prescribed for?

"Prednisolone is a medicine that is used to treat various health conditions. These health conditions include allergies, blood disorders, skin diseases, inflammation, infections, and certain cancers. Prednisolone can also help to prevent organ rejection after a transplant. This medicine works by reducing swelling (inflammation). Prednisolone can also help to calm down your immune system."

Answered by AI

How long does it take for Pediapred to work?

"It usually takes 3 to 10 days to treat this, although it can take longer."

Answered by AI

What is Pediapred used for?

"This drug is used to treat a variety of conditions, including arthritis, blood disorders, immune system disorders, skin and eye conditions, breathing problems, cancer, and severe allergies. It works by decreasing the immune system's response to diseases, which decreases symptoms such as pain, swelling, and allergic reactions."

Answered by AI

Clinical Trials for Pediapred

Image of The University of British Columbia in Vancouver, Canada.

Treatment for Crohn's Disease

9 - 17
All Sexes
Vancouver, Canada

Children with Crohn's disease (CD), a type of Inflammatory Bowel Disease (IBD), often face serious health challenges, including poor growth, frequent hospital stays, and long-term medication use. Although biologic drugs like infliximab, an anti-TNFα (Tumor necrosis factor α) medication, have improved treatment, they don't work for everyone: many children still experience symptoms or disease flare-ups. Nutritional therapies, especially the Crohn's Disease Exclusion Diet (CDED), may help improve treatment outcomes. This study will assess whether starting CDED at the same time as infliximab leads to better responses to treatment. The goal of this study is to improve how well children respond to therapy, reduce drug exposure, and support better long-term health.

Waitlist Available
Has No Placebo

The University of British Columbia

Kevan Jacobson, MBBCh, FRCP, FRCPC, AGAF, CAGF

Image of National Institutes of Health Clinical Center in Bethesda, United States.

Treatment for Nephrotic Syndrome

18 - 120
All Sexes
Bethesda, MD

Background: Abnormal fats in the blood can lead to many problems, including heart disease. Researchers want to learn more about how eating meals with different levels of nutrients affects fats in the blood. Specifically, they want to study people with too much body fat, too little body fat, and a kidney problem called nephrotic syndrome. Objective: To learn more about how different types of foods affect fat levels in the blood. Eligibility: People aged 18 years or older with a health condition that affects how their body handles fats. Healthy volunteers are also needed. Design: Participants will have 2 overnight stays in the clinic within 6 months. At each visit, after staying overnight, they will eat a breakfast casserole. At 1 visit, breakfast will be a high-fat, low carbohydrate meal. At the other, it will be a high-carbohydrate, low-fat meal. Participants will have a tube inserted into a vein in their arm. They will have blood drawn via the tube 12 times in 8 hours: 2 times before they eat the breakfast and 10 times after. Participants will have other tests during their stays: A resting metabolic test captures the air they exhale and measures how much energy they use at rest. A dual energy X-ray absorptiometry (DXA) scan measures how much fat and muscle they have. A Fibroscan is a special type of ultrasound of the liver. A body surface scan uses lasers to measure the total area of the body. A bioelectric impedance (BIS) exam measures how fast small electric currents move through their body. Participants may opt to have a third visit. At this visit, the breakfast will be high in protein.

Phase 2
Waitlist Available

National Institutes of Health Clinical Center

Rebecca J Brown, M.D.

Image of MUHC - Montreal General Hospital in Montreal, Canada.

Ustekinumab for Crohn's Disease and Ulcerative Colitis

18+
All Sexes
Montreal, Canada

The goal of this clinical trial is to evaluate whether disease remission can be maintained when biologic therapy is reduced in patients with Crohn"s disease (CD) and ulcerative colitis (UC) taking ustekinumab (UST). The main question it aims to answer is: Can we de-escalate UST subcutaneous dose either from every 4 weeks (Q4) to every 8 weeks (Q8) or every 8 weeks (Q8) to every 12 weeks (Q12) in CD or UC patients in deep remission without loosing their response? Researchers will follow UST blood levels, inflammation markers and intestinal mucosa integrity and to see if UST dose can be reduced while maintaining clinical remission. Participants will: Change UST dosing from Q4 to Q8 or from Q8 to Q12. Visit the clinic once every 12 weeks for checkups and tests.

Phase 4
Recruiting

MUHC - Montreal General Hospital

Janssen Inc.

Have you considered Pediapred clinical trials?

We made a collection of clinical trials featuring Pediapred, we think they might fit your search criteria.
Go to Trials

Have you considered Pediapred clinical trials?

We made a collection of clinical trials featuring Pediapred, we think they might fit your search criteria.
Go to Trials
Image of UPMC Children's Hospital of Pittsburgh in Pittsburgh, United States.

AQI Information for Asthma

8 - 17
All Sexes
Pittsburgh, PA

The goal of this clinical trial is to learn if adding Air Quality Index (AQI) information to asthma action plans works to improve asthma outcomes in children. It will also learn about children with asthma who report being more sensitive to outdoor air pollution. The main questions it aims to answer are: * Does adding either information about the EPA-AQI or commercial AQI improve asthma outcomes over time? * Are there changes in nasal gene expression in children with asthma who report they are more sensitive to outdoor air pollution? Researchers will compare EPA-AQI and the commercial-AQI groups to a control group to either AQI works to improve asthma. Participants will: * Receive standardized outdoor air pollution education and an asthma action plan * Provide nose and blood specimens * Have visits every 4 weeks for 48 weeks, 10 will be conducted by telephone calls and 3 visits will be in person.

Waitlist Available
Has No Placebo

UPMC Children's Hospital of Pittsburgh

Franziska Rosser, MD MPH

Image of Investigative Site in Beverly Hills, United States.

VENT-03 for Lupus

18 - 70
All Sexes
Beverly Hills, CA

The goal of this clinical trial is to learn if VENT-03 works to treat patients with cutaneous lupus erythematosus (CLE) who may or may not have systemic lupus erythematosus (SLE). Another goal is to learn about the safety of VENT-03 and how it is processed by the body. The main questions it aims to answer are: * Does VENT-03 affect the activity and severity of CLE? * What side effects do participants have when taking VENT-03? Researchers will compare VENT-03 to a placebo (a look-alike substance that contains no drug) to see if VENT-03 works to treat patients with CLE. Participants will: * Take VENT-3 or a placebo every day for 4 weeks, then all participants will switch to VENT-03 for another 8 weeks; * Visit the clinic once a month for checkups and tests.

Phase 2
Recruiting

Investigative Site (+9 Sites)

Ventus Therapeutics U.S., Inc.

Image of Sunnybrook Health Sciences Centre in Toronto, Canada.

Steroids for Rheumatoid Arthritis

18+
All Sexes
Toronto, Canada

People living with rheumatoid arthritis (RA) often experience flares-periods where their symptoms suddenly get worse. These flares can cause significant pain, make it harder to move and do daily activities, and lower overall quality of life. Doctors often treat flares with medications called glucocorticoids (GCs), which reduce inflammation. These medications can be taken by mouth (oral/PO) or given as a single injection into the muscle (intramuscular/IM). However, it's not clear which option works better from the patient's point of view-especially when it comes to relief of symptoms, improvements in function, and satisfaction with treatment. Most research so far has focused on how well the drugs control the disease, rather than how they impact the patient's overall experience. Research Questions: 1. Does a single GC injection work just as well as taking pills over a few weeks in improving symptoms reported by patients? 2. How do the two treatments compare in terms of symptom relief, ability to function, and patient satisfaction? 3. What do patients think and feel about using GCs to treat RA flares? What the Investigators Think: The investigators believe that a one-time GC injection is just as good as taking pills for a few weeks when it comes to managing RA flares. In fact, the injection might even be safer and preferred by patients. What the Investigators are Doing: The investigators will study 220 adults with RA who are currently having a flare (with at least 3 swollen and tender joints). These patients will be recruited from rheumatology clinics at the University of Toronto and must not have used GCs in the past month. They will be randomly assigned to receive either: A single injection (Methylprednisolone 120 mg), or Oral pills (Prednisone starting at 15 mg daily and tapering down over 3 weeks). The main thing the investigators will look at is how much better patients feel after 6 weeks, based on a questionnaire designed to measure RA flares. The investigators will also look at how well they function, how satisfied they are with the treatment, and whether they had any side effects. In addition, 20 patients (10 from each group) will be interviewed to understand their experiences and opinions about flare treatment in more detail. Why This Is Possible: The investigators have already surveyed University of Toronto rheumatologists who support the idea and provided input on study design. The investigators have also partnered with experts in research methods, national arthritis organizations, and patient groups to make sure the study is relevant and meaningful. Ethics approval has been obtained. Why It Matters: RA flares can have a major impact on people's lives. While current treatments help control inflammation, the investigators need to better understand how these treatments affect people from their own perspective. This study will shift the focus to what matters most to patients, helping doctors and patients choose the best treatment based not only on medical results but also on the patient's experience. This could lead to more effective and personalized care for people living with RA.

Phase 4
Waitlist Available

Sunnybrook Health Sciences Centre (+4 Sites)

Have you considered Pediapred clinical trials?

We made a collection of clinical trials featuring Pediapred, we think they might fit your search criteria.
Go to Trials